These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 16924360

  • 21. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.
    Sundel RP, Baker AL, Fulton DR, Newburger JW.
    J Pediatr; 2003 Jun; 142(6):611-6. PubMed ID: 12838187
    [Abstract] [Full Text] [Related]

  • 22. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.
    Qin L, Saumu MT, Wang H, Shi H, Hu X, Cheng P.
    J Huazhong Univ Sci Technolog Med Sci; 2005 Jun; 25(3):348-50, 370. PubMed ID: 16201293
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
    Kobayashi T, Kobayashi T, Morikawa A, Ikeda K, Seki M, Shimoyama S, Ishii Y, Suzuki T, Nakajima K, Sakamoto N, Arakawa H.
    J Pediatr; 2013 Aug; 163(2):521-6. PubMed ID: 23485027
    [Abstract] [Full Text] [Related]

  • 24. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease.
    Okada K, Hara J, Maki I, Miki K, Matsuzaki K, Matsuoka T, Yamamoto T, Nishigaki T, Kurotobi S, Sano T, Osaka Kawasaki Disease Study Group.
    Eur J Pediatr; 2009 Feb; 168(2):181-5. PubMed ID: 18446365
    [Abstract] [Full Text] [Related]

  • 25. Diagnosis, treatment and outcome of Kawasaki disease in an Australian tertiary setting: a review of three years experience.
    Singh-Grewal D, Wong M, Isaacs D.
    J Paediatr Child Health; 2005 Feb; 41(9-10):495-9. PubMed ID: 16150066
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Efficacy and safety of glucocorticoids in addition to intravenous immunoglobulin in the initial treatment of Kawasaki disease: a meta-analysis of randomized trials].
    Hu JW, Zhou ZS, Yang L, Zheng CN, Wang KD.
    Zhonghua Yi Xue Za Zhi; 2011 May 17; 91(18):1259-64. PubMed ID: 21756798
    [Abstract] [Full Text] [Related]

  • 28. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.
    Hashino K, Ishii M, Iemura M, Akagi T, Kato H.
    Pediatr Int; 2001 Jun 17; 43(3):211-7. PubMed ID: 11380911
    [Abstract] [Full Text] [Related]

  • 29. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin.
    Tsai MH, Huang YC, Yen MH, Li CC, Chiu CH, Lin PY, Lin TY, Chang LY.
    J Pediatr; 2006 Jan 17; 148(1):38-43. PubMed ID: 16423595
    [Abstract] [Full Text] [Related]

  • 30. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.
    Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, Matsuishi T.
    J Pediatr; 2006 Aug 17; 149(2):237-40. PubMed ID: 16887442
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease.
    Lee KY, Lee HS, Hong JH, Han JW, Lee JS, Whang KT.
    J Trop Pediatr; 2005 Apr 17; 51(2):98-101. PubMed ID: 15677370
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Steroid pulse therapy].
    Miura M.
    Nihon Rinsho; 2014 Sep 17; 72(9):1631-5. PubMed ID: 25518414
    [Abstract] [Full Text] [Related]

  • 38. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
    Sato S, Kawashima H, Kashiwagi Y, Hoshika A.
    Int J Rheum Dis; 2013 Apr 17; 16(2):168-72. PubMed ID: 23773640
    [Abstract] [Full Text] [Related]

  • 39. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
    Xie T, Wang Y, Fu S, Wang W, Xie C, Zhang Y, Gong F.
    Pediatr Rheumatol Online J; 2017 Mar 21; 15(1):17. PubMed ID: 28320400
    [Abstract] [Full Text] [Related]

  • 40. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
    Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.
    Zhonghua Er Ke Za Zhi; 2006 Dec 21; 44(12):891-5. PubMed ID: 17254453
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.